Jade Biosciences, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Jade Biosciences is in Stage 4, the downtrend phase, now in its first week (since Oct 16, 2026). It closed at $14.91, 44.5% below its 52-week high and below its 200-day average, which is falling.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. More about the company

$14.91

-1.45% today

$948M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is JBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 18w

S1 19w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 5w → S2 18w → S3 6w → S4 13w → S1 19w → S4 8w → S3 3w → S2 5w → S3 2w → S4 10w → S1 1w → S4 6w → S1 4w → S2 17w → S3 4w → S2 13w → S3 6w → S2 4w → S3 4w → S4 1w current

Total tracked: 165 weeks across 21 stage runs.

JBIO among Biotechnology91st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…91	JBIOJade Biosciences, Inc.	Stage 4 · wk 1	86	+1.4%

vs 52W High

-44.5%

$8.95 lo$26.85 hi

44.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-18.2%

200 DMA: $18.22 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.62x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+1.4%

-25.7%

-40.9%

YTD

+5.3%

+48.7%

Scan Membership

Breakout Watch

Latest: 2025-04-22

5 appearances in last 60 days. First seen: 2022-05-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.62x

2026-10-21S4

Wk 1 · Vol 0.89x

2026-10-20S4

Wk 1 · Vol 0.96x

2026-10-19S4

Wk 1 · Vol 0.91x

2026-10-16S43→4

Wk 1 · Vol 1.07x

2026-10-15S3

Wk 4 · Vol 1.13x

2026-10-14S3

Wk 4 · Vol 1.26x

2026-10-13S3

Wk 4 · Vol 1.45x

2026-10-12S3

Wk 4 · Vol 1.51x

2026-10-09S3

Wk 3 · Vol 0.82x

2026-10-08S3

Wk 3 · Vol 1.91x

2026-10-07S3

Wk 3 · Vol 1.09x

Moving averages & range

50 DMA

$17.54

200 DMA

$18.22

52W High

$26.85

52W Low

$8.95

5D Low

$13.47

Resistance levels (recent highs)

20d High

$15.13

60d High

$24.71

120d High

$25.81

250d High

$26.85

Next resistance

+1.5%

to 20d High

Dividend Yield

0.00%

P/B 2.2

Jade Biosciences: quick answers

What stage is Jade Biosciences in?

As of Oct 22, 2026, Jade Biosciences (JBIO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 16, 2026 and is in its first week there. What the four stages mean

Is Jade Biosciences in an uptrend?

No. Jade Biosciences is in a Stage 4 downtrend. It trades 18.2% below its 200-day average, which is falling.

How far is Jade Biosciences from its 52-week high?

Jade Biosciences closed at $14.91 on Oct 22, 2026, 44.5% below its 52-week high of $26.85. Its 52-week low is $8.95.

How has Jade Biosciences performed over the past year?

As of Oct 22, 2026, Jade Biosciences is up 48.7% over the past year and up 5.3% so far in 2026.

Which sector and industry is Jade Biosciences in?

Jade Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.